Media headlines about Tobira Development (NASDAQ:TBRA) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tobira Development earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.4301782424348 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

COPYRIGHT VIOLATION WARNING: “Tobira Development (TBRA) Receives Daily News Impact Rating of 0.20” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/10/tobira-development-tbra-receives-daily-news-impact-rating-of-0-20.html.

Tobira Development Company Profile

Tobira Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company’s product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure.

Receive News & Stock Ratings for Tobira Development Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Development Inc and related stocks with our FREE daily email newsletter.